Quick Answer
VYNE Therapeutics Inc. reported Cash and Equivalents of $24.03 million for fiscal year 2025.
VYNE Therapeutics Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $24.03M | +20.6% |
| 2024 | $19.93M | -34.9% |
| 2023 | $30.62M | -0.9% |
| 2022 | $30.91M | -26.8% |
| 2021 | $42.25M | -26.6% |
| 2020 | $57.56M | +31.5% |
| 2019 | $43.76M | +57.0% |
| 2018 | $27.87M | +173.1% |
| 2017 | $10.21M | +153.4% |
| 2016 | $4.03M | -90.8% |
| 2015 | $43.81M | +15946.9% |
| 2014 | $273.0K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $22.05M | -25.5% | -21.8% |
| March 31, 2025 | $28.21M | +48.0% | +41.6% |
| December 31, 2024 | $19.93M | -34.9% | +22.5% |
| September 30, 2024 | $16.27M | +5.3% | -45.0% |
| June 30, 2024 | $29.61M | +43.5% | +55.3% |
| March 31, 2024 | $19.07M | -36.9% | -37.7% |
| December 31, 2023 | $30.62M | -0.9% | +98.2% |
| September 30, 2023 | $15.45M | -56.5% | -25.1% |
- VYNE Therapeutics Inc. showed an increase of +20.6% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2014–2025 period, VYNE Therapeutics Inc.’s cash and equivalents has grown by 8701.1% (from $273.0 thousand to $24.03 million).
- The most recent figure is from VYNE Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: